US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II ...

CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...

For example, should DUPIXENT slow to 15% growth, while LIBTAYO continues rapidly as the label is expanded to include CSCC an overall revenue growth for Regeneron of ~10% seems achievable.

READ MORE: THIO-Libtayo Regimen Is ‘Encouraging’ for Relapsed NSCLC THIO-101 was an open-label, multicenter study that enrolled adult patients with advanced NSCLC who experienced disease progression ...

Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo ...

The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer (NSCLC) may be eligible for treatment with Libtayo monotherapy1 based on the results of the Phase III ...